MDGL Quote, Financials, Valuation and Earnings

Amgen, Inc. has a net margin of -39.75% compared to Madrigal Pharmaceuticals, Inc.'s net margin of 33.55%. Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56% beat Amgen, Inc.'s return on equity of 95.55%.

Madrigal Pharmaceuticals, Inc. has a consensus price target of $603.47, signalling upside risk potential of 0.76%. On the other hand Amgen, Inc. has an analysts' consensus of $325.88 which suggests that it could fall by -2.12%. Given that Madrigal Pharmaceuticals, Inc. has higher upside potential than Amgen, Inc., analysts believe Madrigal Pharmaceuticals, Inc. is more attractive than Amgen, Inc..

Madrigal Pharmaceuticals, Inc. has a beta of -1.034, which suggesting that the stock is 203.399% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.

Madrigal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.86% to investors and pays a quarterly dividend of $2.38 per share. Madrigal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.

Madrigal Pharmaceuticals, Inc. quarterly revenues are $287.3M, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M is lower than Amgen, Inc.'s net income of $3.2B. Notably, Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Amgen, Inc.'s PE ratio is 25.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals, Inc. is 17.93x versus 5.02x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics, Inc. has a net margin of -39.75% compared to Madrigal Pharmaceuticals, Inc.'s net margin of 10.24%. Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Madrigal Pharmaceuticals, Inc. has a consensus price target of $603.47, signalling upside risk potential of 0.76%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.83 which suggests that it could grow by 7.02%. Given that Amicus Therapeutics, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Amicus Therapeutics, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Madrigal Pharmaceuticals, Inc. has a beta of -1.034, which suggesting that the stock is 203.399% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.

Madrigal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals, Inc. quarterly revenues are $287.3M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals, Inc. is 17.93x versus 7.29x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of -39.75% compared to Madrigal Pharmaceuticals, Inc.'s net margin of -259.95%. Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56% beat Insmed, Inc.'s return on equity of -193.23%.

Madrigal Pharmaceuticals, Inc. has a consensus price target of $603.47, signalling upside risk potential of 0.76%. On the other hand Insmed, Inc. has an analysts' consensus of $214.78 which suggests that it could grow by 20.84%. Given that Insmed, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Insmed, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Madrigal Pharmaceuticals, Inc. has a beta of -1.034, which suggesting that the stock is 203.399% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.

Madrigal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals, Inc. quarterly revenues are $287.3M, which are larger than Insmed, Inc. quarterly revenues of $142.3M. Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M is higher than Insmed, Inc.'s net income of -$370M. Notably, Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals, Inc. is 17.93x versus 75.70x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -39.75% compared to Madrigal Pharmaceuticals, Inc.'s net margin of 31.72%. Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56% beat Eli Lilly & Co.'s return on equity of 106.26%.

Madrigal Pharmaceuticals, Inc. has a consensus price target of $603.47, signalling upside risk potential of 0.76%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 1.44%. Given that Eli Lilly & Co. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Eli Lilly & Co. is more attractive than Madrigal Pharmaceuticals, Inc..

Madrigal Pharmaceuticals, Inc. has a beta of -1.034, which suggesting that the stock is 203.399% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Madrigal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Madrigal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Madrigal Pharmaceuticals, Inc. quarterly revenues are $287.3M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 53.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals, Inc. is 17.93x versus 16.54x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.